Drug Profile
Research programme: siRNA therapeutics - Silence Therapeutics
Alternative Names: Atu014; Atu093; Atu111; Atu134; Atu150; Atu195; AtuRNAi; Soluble Fms-like Tyrosine Kinase-1-specific SiRNALatest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Atugen AG
- Developer Charite of Berlin; McGill University; Sanofi; Silence Therapeutics; Silence Therapeutics plc
- Class Antihyperglycaemics; Antihypertensives; Antineoplastics; Small interfering RNA
- Mechanism of Action Endothelin A receptor antagonists; Protein kinase N3 inhibitors; RNA interference; Vascular endothelial growth factor receptor-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acute lung injury; Solid tumours
Highest Development Phases
- No development reported Acute lung injury; Preeclampsia; Pulmonary arterial hypertension
- Discontinued Diabetes mellitus; Solid tumours; Wounds
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 28 Oct 2021 No recent reports of development identified for preclinical development in Preeclampsia in England (IV)
- 28 May 2020 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in England (Parenteral)